key: cord-0700714-bil9wd69 authors: Iorio, Giuseppe Carlo; Ricardi, Umberto; Dal Pra, Alan title: Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic date: 2020-11-18 journal: Front Oncol DOI: 10.3389/fonc.2020.617302 sha: 3899f91a0d478ec58cb02393924efb91bf02167f doc_id: 700714 cord_uid: bil9wd69 nan Lymphopenia has been previously correlated with vertebral bone marrow (BM) radiation volumes in esophageal cancers (17) . This is in line with data reported for patients undergoing pelvic nodal radiotherapy (PNRT), as BM dose-volume parameters have been associated with the onset of HT, particularly leukopenia (6, 7, 20) . Although BM represents only part of the pelvic reservoir lymphoid organs together with lymph nodes, circulating lymphocytes, and gut mucosa, radiation-induced BM suppression is a predictor of leukopenia and lymphopenia (6, 7, 20, 21) . BM stem cells are exquisitely radiosensitive and, in the average adult population, half of the hematopoietically active BM (aBM) is located within pelvic bones and lumbar vertebrae (6, 7, 20, 21) . Regarding dosimetric parameters predictive of HT, data from cervical cancer suggest that volumes receiving low-dose are important, e.g., pelvic BM V10 < 90%-95% and V20 < 76%-80% to avoid grade 2-3 HT, especially leukopenia (6, 22). In the RTOG-0418, which included cervical and endometrial cancer patients, BM V40 and median BM dose were linked with higher rates of grade 2 or worse HT (23) . Techniques to spare BM, like the employment of PET-guided aBM sparing, have resulted in a significant decrease in HT, particularly grade 3 or worse neutropenia (24) . Similar to cervical cancer, an association between larger volumes receiving low-doses and HT emerged from anal cancer studies (25, 26) . Bazan et al. also highlighted the role of the mean pelvic BM dose as a useful toxicity predictor for anal cancer patients, recommending a mean dose at <22.5-25 Gy (25) , and supporting the hypothesis of considering the pelvic BM as a parallel organ when predicting HT (25, 27) . Several studies addressed radiation-induced BM suppression in rectal cancer patients undergoing PNRT. In a series of 120 rectal cancer patients treated with neoadjuvant pelvic radiotherapy and concurrent 5-fluorouracil-based CT, Yang et al. found that coxal BM V45 (p = 0.03) and sacral BM V45 (p = 0.03) were associated with a lower leukocyte count and lower absolute neutrophil count ratio at nadir, respectively. Of interest, among all HTs, lymphopenia occurred most frequently: grade 2 lymphopenia was observed in 97.5% of patients while grade 3 in 56.7% (8). In a mixed population of different pelvic cancers, including rectal, cervical, anal, vaginal, and bladder cancer patients, McGuire et al. reported lymphopenia as the most common recorded toxicity (28) . Chronically lower lymphocytes counts (at 1-2 years after treatment) have been observed in prostate cancer patients undergoing PNRT (20, 29) . In this regard, Sini et al. highlighted a higher risk of both acute and late lymphopenia with BM mediumhigh doses exposure (≥40Gy) (20) . Accordingly, data of an Italian multicentric study with 406 prostate cancer patients treated with PNRT showed an association between large nodal volumes (>900 cc) and acute grade 3 or worse and late grade 2 or worse lymphopenia (lasting at least 1 year) (29) . Thus, prostate cancer radiotherapy is a particularly interesting scenario for radiation-induced HT studies, given the increasing use of larger RT volumes to the pelvis. In times of pandemic, radiation oncologists should be cautious about utilizing large elective radiation volumes, particularly when the benefit is uncertain, to avoid suppression of reservoir lymphoid organs (30) . Perhaps short-fractionation schedules, widely preconized during this outbreak (30) , could have less impact on hematologic counts, particularly extremehypofractionation with steep dose-gradients (11) . The low entrance-dose and sharp fall-off of proton therapy have been shown to decrease the RIL risk and severity by minimizing unintended irradiation to circulating immune cells (31) . Proton therapy offers dosimetric advantages in BM sparing when delivering PNRT as compared to intensity-modulated radiotherapy and volumetric arc therapy (32, 33) . Therefore, stereotactic body radiotherapy (SBRT) and proton therapy may represent promising approaches for "lymphocyte sparing radiotherapy" (21, 31) . Additionally, brachytherapy, given the favorable dose distribution to normal tissues, should also be kept in mind for more effective "immune-sparing" radiotherapy approaches (34) (35) (36) (37) . Finally, although there is important evidence addressing radiation-induced HT and lymphopenia, there is still a great deal of uncertainty on its long-term oncological implications. In light of the importance of a normal lymphocyte count during the COVID-19 pandemic, we face an unprecedented opportunity for further elucidation of the impact of RIL and "lymphocytesparing" strategies. All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication. COVID-19: consider cytokine storm syndromes and immunosuppression Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer Higher Radiation Dose to Immune System is Correlated With Poorer Survival in Patients With Stage III Non-small Cell Lung Cancer: A Secondary Study Cooperative Group Trial (NRG Oncology RTOG 0617) Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyterich Organs When Combining Radiotherapy With Immunotherapy Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2) Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients PV-0627: Hematologic toxicity after whole-pelvis irradiation: results of a longitudinal observational study Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19 Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties Absolute volume of active bone marrow and total bone marrow spared in anal cancer patients using intensity modulated proton versus volumetric arc therapy Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors Changes in natural killer cell activity by external radiotherapy and/or brachytherapy COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Iorio, Ricardi and Dal Pra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.